Company intelligence / Profile preview

Adgero Biopharmaceuticals

Princeton, New Jersey, United States

Ownership: Private
Development stage: Other

Overview

REM-001 Therapy, a photodynamic therapy platform, had been studied in four Phase 2/3 trials in cutaneous metastatic breast cancer with reported clinical efficacy of about 80% complete responses in evaluable lesions and a safety database of ~1,100 patients across multiple indications; Adgero was preparing a confirmatory lead‑in study intended to transition to a Phase 3 pivotal trial before its acquisition.

Therapeutic areas: OncologyNephrology
Modalities: Small moleculeDevice
Industry: Biotech

Partnerships

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (strategic investment and potential Asia collaboration around PDT)Global Coalition for Adaptive Research (GCAR) / GBM AGILE noted as Kintara partnership for other asset, but not specific to Adgero platform

Beyond the preview

Go deeper on Adgero Biopharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Adgero Biopharmaceuticals.

Explore the full profile